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The composition and condition of membrane lipids, the morphology of erythrocytes, and hemoglobin distribution were explored
with the help of laser interferencemicroscopy (LIM) and Raman spectroscopy. It is shown that patients with cardiovascular diseases
(CVD) have significant changes in the composition of their phospholipids and the fatty acids of membrane lipids. Furthermore,
the microviscosity of the membranes and morphology of the erythrocytes are altered causing disordered oxygen transport by
hemoglobin. Basic therapy carried out with the use of antiaggregants, statins, antianginals, beta-blockers, and calcium antagonists
does not help to recover themorphofunctional properties of erythrocytes. Based on the results the authors assume that, for the relief
of the ischemic crisis and further therapeutic treatment, it is necessary to include, in addition to cardiovascular disease medicines,
medication that increases the ability of erythrocytes’ hemoglobin to transport oxygen to the tissues. We assume that the use of
LIM and Raman spectroscopy is advisable for early diagnosis of changes in the structure and functional state of erythrocytes when
cardiovascular diseases develop.
1. Introduction
Nowadays diseases of the cardiovascular system occupy a
leading place among the major causes of disabilities and
mortality of the active labour force not only in Russia but
throughout the world [1, 2]. Notwithstanding the intro-
duction of new highly effective methods of diagnosis and
treatment into clinical practice, mortality from ischemic
heart disease (IHD) remains high. Among the IHD risk
factors, one of the first causes rests with arterial hypertension,
which for its prevalence is called a “disease of civilization.”
The most important and frequent manifestation of IHD is
angina pectoris.
The pathophysiology of most cardiovascular diseases
attributes one of the key places to hypoxia, which causes
disorders of the gas-transport function of blood and, inmany
cases, reduces the efficiency of oxygen transport carried out
by erythrocytes. The primary reason is attributed to the
disorders in structure and function of endothelium of blood
vessels, while the role of erythrocytes and their oxygen-
transport ability in the development of vascular diseases
remains insufficiently studied [2, 3].
Oxygen-transport function of erythrocytes in peripheral
blood depends on many factors, where of great importance
is the change in conformation of hemoglobin (Hb) and its
affinity to oxygen (O2). The use of Raman spectroscopy (RS)
made it possible to identify changes in the conformation of
hemoporphyrin in patients with severe arterial hypertension
and under the therapeutic interval hypoxia in patients with
stable effort [4] and in patients with circulatory failure [5–7].
It is important to highlight that oxygen-binding and
oxygen-transport properties of hemoglobin depend on
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the morphological and functional condition of erythrocytic
membranes [8, 9].
Current researches pay little attention to one of the most
important barriers of oxygen to hemoglobin, that is, the lipid
bilayer of erythrocytic membranes, which depends on indi-
vidual phospholipids, the degree of oxidation, and the ratio
of saturated and unsaturated fatty acids. Also insufficiently
studied is the mechanism of oxygen transport through the
lipid bilayer. And it should be emphasised that a significant
part of phospholipids and their metabolites is involved in the
regulation of various functions through receptor systems [10–
12].
A special role is assigned to oxidative stress being devel-
oped in case of lipidic pathologies and the substrates of such
development are unsaturated fatty acids. Modification of the
composition and structural arrangement of phospholipids in
cellmembranesmay cause disruption of ion transport [13, 14].
Based on this far incomplete list of lipids roles in cell’s
condition it can be assumed that disorders in lipid composi-
tion and condition of erythrocyte membranes play a key role
in the development of many cardiovascular diseases [15, 16].
Structural changes of erythrocytic membranes, including
the change in mobility of membrane proteins, causes the
increased susceptibility to proteolysis [17, 18].
When cardiovascular disease develops it is the cytoarchi-
tectonics of formed elements that underlies the changes in the
structural-functional condition of erythrocytic membranes
in healthy people as well as among the diseased. Assessment
of surface changes in cytoarchitectonics may serve as an
indicator of the efficient therapy [7].
It is of great current interest and importance from a prac-
tical point of view to study the erythrocyte cytoarchitectonics
and its rheological properties as an integral indicator of the
development of angina pectoris.
It is yet to be firmly concluded whether there is a relation-
ship between disorders in lipid composition of membranes,
changes of morphometric parameters of erythrocytes, and
conformational changes of hemoglobin hemoporphyrin in
norm and in pathological conditions associated with the
development of hypoxia in the body which remains not
thoroughly investigated. Considering the above, the aim of
our research was to examine changes in lipid composition
ofmembranes, cytoarchitectonics of erythrocytes, conforma-
tion of hemoglobin hemoporphyrin and its oxygen-transport
function in respect to the clinical course of angina pectoris,
and the presence of primary arterial hypertension in patients’
anamnesis.
2. Materials and Methods
The research was carried out following the approval of the
Local ethics Committee of Mordovia State University on
the basis at the Mordovian Republican Hospital of War
Veterans in accordance with the principles of Good Clinical
Practice. Having obtained informed consent for participation
in the research, we examined 39 patients at the cardiology
department, all males aged from 46 to 63 years (average age
of 54.5 ± 3.8 years). Further inclusionary criteria required
patients to be nonsmokers, with no history of hereditary
anomalies and a body mass index ranging from 23 to 29.
Patients were divided into 2 groups depending on disease:
Group 1—stable angina, 𝑛 = 21;
Group 2—stable angina on the top of primary arterial
hypertension (stage 3, risk 3), 𝑛 = 18.
The research did not include patients with a history of
liver, kidney, lung disease, diabetes, systemic diseases, or
malignancy.
The treatment was administered using a unified scheme
and antianginal drugs, ACE inhibitors, angiotensin II antago-
nists, beta-blockers, calcium antagonists, electrolytes, antiag-
gregants, statins, and diuretics. The examination was carried
out before and on the tenth day of treatment.
The control group consisted of 19 apparently healthymale
donors of the republican station of blood transfusion of a
similar age (the average age being 50.5 ± 1.9 years), without
evidence of CVD during preventative examinations.
Research results were obtained from patients’ blood
samples, aseptically taken from the cubital vein in the volume
of 5mL in a fasting state.
Erythrocytes were obtained by centrifugation of whole
blood at 1500×g for 10min; then a small portion of sediment
was resuspended in the washing fluid; the latter was used
for microscopy, while the other part was used to obtain
membranes.
To isolate membranes from human erythrocytes sedi-
ments of erythrocytes were hemolysed in a cooled to 0∘C
solution of 5mMNaH2PO4; 0.5mMPMSF (phenylmetylsul-
fonylfluoride) pH 8.0 (lysis solution).The ratio of erythrocyte
sediment to lysis solution was 1 : 20 (V : V).
The mixture was left for 10min at 4∘C and then cen-
trifuged at 20000×g for 40 minutes (temperature 0∘C). The
supernatant was removed; the sediment was resuspended in
lysis solution and centrifuged at 20000×g for 40 minutes
(temperature 0∘C). The procedure was repeated three times.
Extraction of membrane lipids was performed by using
Bligh and Dyer’s method [19]. To separate phospholipids
we used one-dimensional chromatography in the system of
solvents: chloroform/methanol/water/ammonia (60/34/4/2)
[20, 21] and chloroform/methanol/glacial acetic acid/water
(60/50/1/4) [22].
The resulting phospholipids were eluted with a mixture
of chloroform :methanol (2 : 1). Methylation of fatty acids
was performed by using Morrison and Smith’s method [23].
Separation of methyl esters of fatty acids was performed
on a gas chromatograph GC-2010 Plus (Shimadzu, Japan).
The software package GCsolution, Shimadzu, was used. The
coefficient of saturation was calculated as the ratio between
the sum of saturated and unsaturated fatty acids.
The structure of erythrocytes and hemoglobin content
was found by method of laser interference microscopy (LIM)
in vitro [24–30] with the use of device MJJ-4M (Russia).
The sediment (deposit) of erythrocytes after centrifugation
was diluted 20 times with washing medium (10mm of
KH2PO4, 3.5mm of KCl, 1.5mm of MgCl2, 145mm of NaCl,
and 6mm of glucose, pH 7.4). 1mcL of the erythrocytes’
suspension was placed on a mirror glass; a smear was
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prepared and covered with cover glass. The measurements
were carried out at room temperature (18–22∘C). For LIM
examination we received image of 10 sites with a monolayer
arrangement of cells in the interference channel and the
reflected light in each sample. The resulting images of red
blood cells were processed using FIJI [31].
The condition of human erythrocytes was assessed by
registering the mean value of optical path difference (OPD)
and the phase image area of erythrocyte, the value of which
was calculated using FIJI software [31]. To get a reliable result,
indicatorswere calculated, feeding upon at least 100 cells from
each sample.
Additionally we had to evaluate the phase volume of
erythrocyte by the formula below:
𝑉cell =
Φmean𝑆
𝑛cell − 𝑛𝑚
, (1)
where 𝑆 is the phase image area of erythrocyte,Φmean is mean
value of the measured parameter, optical path difference
(OPD), proportional to the thickness of erythrocyte, 𝑛cell
is erythrocyte refraction index equal to 1,405, and 𝑛𝑚 is
refraction index of normal saline that was equal to 1,333.
Conformation and properties of hemoglobin were
defined by Raman spectroscopy on the device In Via
Renishaw (UK) with short-focus extreme aperture lens
monochromator (focus distance not more than 250mm)
[4, 9, 32, 33]. For excitation of Raman spectra we used the
laser with wavelength 532 nm, maximum power 100mW, and
objective 100x and CCD detector for recording data (1024 ×
256 pixels with Peltier cooling to –70∘C), 1800 lines/mm.The
digitised spectra were processed with WIRE 3.3. Reference
line correction and smoothing of the spectra were carried
out.
The erythrocytes suspension smear was studied on the
object glass. Hemoglobin spectra bands were traced out at
excitation by laser 532 nm and correlation of bands with
variations of porphyrin linkswas carried out. For each sample
the measurements were taken three times and the resulting
values were averaged. The position and intensity of Raman
scattering (RSc) bands of hemoglobin spectrum depend on
variations of links in a porphyrin ring that allows you to
estimate the conformation of hematoporphyrin (HP), which
is directly related to hemoglobin’s oxygen-binding properties
[32].
To analyse the conformation of hemoglobin’s hemato-
porphyrin (HP) we took into account specific bands of RS
spectrum, which allowed us to explore the conformation of
HP in deoxyhemoglobin (d–Hb) and the ability of d-Hb
to bind ligands, as well as the HP conformation in oxyhe-
moglobin (o–Hb) and the ability of o-Hb to reduce the
oxygen.
In this paper to analyse the conformation and Hb’s \2–
binding properties we drew on the following RS band spectra
of blood (maximumpositions indicated): 1355, 1375, 1550, and
1580 cm−1.
The use of RS-peaks correlations and not their absolute
values is explained by the fact that the absolute value of
spectrum intensity depends on the amount of hemoglobin
and thus amount of erythrocytes in the sample and in the
laser’s focus. Internal normalisation of peaks (on the intensity
of other bands) ensures that the analysed parameters in
different samples do not bear on the amount of hemoglobin
and are determined only by the conformation of hemoglobin
and the relative content of its various forms.
The character of spectra in Raman scattering (RSc) of
hemoprotein hemoglobin [30, 33] allows us to determine
the degree of oxidation of the iron atom included, its spin
state, and the presence of ligands and reflects changes in the
structure of globin, leading to deformation of hemoprotein
and affecting oxygen-binding properties of hemoglobin [6].
The intensity of the spectrum bands 1355 and 1375 cm−1
is related to symmetrical oscillations of pyrrole rings in
deoxyhemoglobin molecules and hemoglobin bound with
ligands, respectively [5]. As the amount of O2 in blood is 3-4
orders higher than the concentrations of other ligands (e.g.,
NO or CO), the intensity of the band 1375 cm−1 is mainly
determined by the content of oxyhemoglobin. Therefore, the
intensity ratio 𝐼1375/(𝐼1355 + 𝐼1375) is proportionate to the
relative amount of oxyhemoglobin in blood. Intensities of
bands 1550 cm−1 and 1580 cm−1 characterise the spin state of
iron in its deoxy- and oxyform, respectively, and thus are a
marker, which assesses the structural characteristics of iron
in a prosthetic group.
This makes possible, using the relationship between the
intensities of bands 𝐼1355/𝐼1550 and 𝐼1375/𝐼1580, evaluating the
ability of molecules of hemoglobin in erythrocytes to bind
and to release oxygen molecules, respectively, with account
to the internal state of hemoglobin molecules. Dividing one
ratio by another (𝐼1355/𝐼1550)/(𝐼1375/𝐼1580) one can obtain a
parameter reflecting the affinity of the hemoglobin molecule
to oxygen in native erythrocytes [9, 30, 32–35].
Statistical processing of experimental results was carried
out in several stages. The first phase evaluated the normality
of the distribution of values for each of the samples; we
used Geary’s criterion [36]. The second stage has assessed
homogeneity of variance. Then ANOVA and ANOVA for
repeated measures were conducted. In the case of statistically
significant differences between themean values, we used post
hoc analysis method of comparison of means by Tukey [37].
The research results are presented as arithmetic means ±
standard deviation (means ± SD).
3. Results
The findings showed that erythrocytic membranes of healthy
people have 5 fractions of phospholipids (PL): sphingomyelin
(SM), phosphatidylcholine (PC), phosphatidylserine (PS),
phosphatidylinositol (PI), phosphatidylethanolamine (PEA),
and diacylglycerol (DAG). The composition of phospho-
lipids’ fatty acids (FA) of erythrocytic membranes included
myristic (14:0), palmitic (16:0), palmitoleic (C16:1), stearic
(C18:0), oleic (C18:1), linoleic (C18:2), linolenic (C18:3),
arachidic (C20:0), gondoinic (C20:1), eicosadienoic (C20:2),
and behenic (C22:0) acids.
The lipid composition of erythrocytic membranes in
patients with stable angina has substantial differences: the
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Figure 1: Change in the amount of phospholipids and lysophospho-
lipids in red blood cells membranes of patients with stable angina
(SA) and stable angina with hypertension (HT): 𝜇g P PLind/mg
P PLgen.
∗∗𝑝 < 0.01; ∗𝑝 < 0.05.
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Figure 2: Change in the amount of phospholipids and lysophospho-
lipids (𝜇g P PLind/mg P PLgen) and free fatty acids (𝜇g P PLind/mg
P PLgen) in erythrocytic membranes of patients with stable angina
(SA) before and after treatment. ∗𝑝 < 0.05.
content of PS,DAG, and SM increases by 18.7; 22.3; and 27.9%,
and the level of PC, PEA, and PI reduces by 19.1; 22.5; and
24.3% (𝑝 < 0.05), respectively, compared to control values
(Figure 1).
Concurrent with this the content of lysophosphatidyl-
choline (LPC), lysophosphatidylethanolamine (LPEA), and
free fatty acids (FFA) increases by 20.8; 18.3; and 24.2% (𝑝 <
0.05), respectively, compared to control values (Figure 1).
Patients with stable angina on top of the primary arterial
hypertension have marked changes in phospholipid compo-
sition of erythrocytic membranes. These differences appear
as the increase in concentration of PS, SM, and DAG by
26.7; 42.6; and 32.3% and the decrease in concentration
of PC, PEA, and PI by 26.1; 29.5; and 30.3% (𝑝 < 0.05),
respectively, compared to control values (Figure 1). Also
notably, the erythrocytes of patients with stable angina on top
of hypertension have the increase in LPC, LPEA, and FFA by
25.8; 28.3; and 31.2% (𝑝 < 0.05), respectively, compared to
control values (Figure 1).
Depletion of erythrocytes by phosphatidylcholine that
forms the outer shell of the lipidmatrix points to the processes
of disintegration of membrane structures, which may cause
their destruction. Moreover, because PC demonstrates the
properties of an inhibitor in processes of lipid peroxidation,
its decreased amount in erythrocytes may lessen antioxidant
protection of cell membranes [38]. The decrease in the
amount of PEA and PC is apparently due to their partial
hydrolysis by phospholipase A2, with simultaneous increase
in monoacylated lysoderivatives—LPC and LFAA. A further
proof to the activation of phospholipase A2 is the findings
on the accumulation of FFA under the same conditions
(Figure 2).
The decrease in the amount of PI in IHD patients can
most likely be attributed to the activation of phospholipase
C that causes PI degradation with the formation of inositol
triphosphate and diacylglycerol, further metabolised into
phosphatidic acid [39]. This is proven by our data on the
increase in the content of DAG (Figure 1).
It is known that one of the important indicators of lipid
biolayer condition is microviscosity, the parameters of which
depend on the fatty acid composition of phospholipids that
form erythrocytic membranes [40].
In all examined fractions of phospholipids, we found the
increase in saturation ratio, which points to the decrease
in the amount of unsaturated and the increase in saturated
fatty acids. Moreover, the most marked changes occur in
erythrocytes of patients with stable angina on a background
of hypertension (Table 1).
Most likely, the increase in phospholipids lysoforms, as
well as the change in the quantitative content and fatty
acid composition of phospholipid fractions, is explained by
the intensification of lipid peroxidation and activation of
phospholipase [41, 42].
Apart from that, the increase in the number of PS may
also point to the intensification of processes of LPO, as PS is
the dominant activator of protein kinase C, the initiation of
which in some cases may alternate with the intensification of
and the weakening of antioxidant defense (AOD) [43].
To confirm our hypothesis, we carried out a research
where it was found that erythrocytes of patients with sta-
ble angina accumulate diene conjugates (DC) and malonic
dialdehyde (MDA), the amount ofwhich increases by 31.2 and
41.4% (𝑝 < 0.05), respectively, compared to control values.
It should be noted that patients with stable angina on the
background of hypertension demonstrate a more intensive
activation of processes of lipid peroxidation (LPO): the level
of DC and MDA in this variant of experiments increases by
38.9% and 52.6% (𝑝 < 0.05), respectively, compared with
donors’ erythrocytes (Figure 3).
The research into biomembranes’ lipid composition of
erythrocytes on the background of treatment revealed an
increase in the amount of PC, PEA, and PI by 13.3; 15.8; and
16.7%, respectively, and the decrease in the amount of LPC
and FFA by 12.2 and 12.5%, respectively, comparedwith blood
of patients suffering from stable angina before treatment
(Figures 1 and 2). Apart from that, the therapy carried out in
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Table 1: The change in saturation ratio (𝑅sat) of individual phospholipid fractions in erythrocytic membranes of patients with stable angina
(SA) and SA with hypertension (HT) on the background of treatment (means ± SD).
Variants of
experiments
𝑅sat PC,
𝜇g Ppch/mg Pfl
𝑅sat PEA, 𝜇g
Ppea/mg Pfl
𝑅sat SM 𝜇g
Psm/mg Pfl
𝑅sat PS 𝜇g
Pps/mg Pfl
𝑅sat PI 𝜇g
Ppi/mg Pfl
𝑅sat DAG 𝜇g
Pdag/mg Pfl
𝑅sat FFA 𝜇g
Pffa/mg Pfl
Donors 1.05 ± 0.021 1.3 ± 0.038 1.7 ± 0.021 1.2 ± 0.023 1.2 ± 0.021 1.95 ± 0.022 1.1 ± 0.02
Patients with SA
before treatment 1.65 ± 0.06
∗ 2.86 ± 0.069∗ 3.23 ± 0.055∗ 1.8 ± 0.051 2.34 ± 0.056∗ 2.71 ± 0.69∗ 2.26 ± 0.094∗
Patients with
SA+HT before
treatment
1.77 ± 0.067∗ 3.92 ± 0.066∗ 3.84 ± 0.05∗ 2.24 ± 0.044∗ 2.87 ± 0.058∗ 2.89 ± 0.061∗ 3.21 ± 0.062∗
Patients with SA
after treatment 1.29 ± 0.063
∗∗ 2.09 ± 0.082 2.58 ± 0.075∗∗ 1.49 ± 0.06 1.62 ± 0.066 2.45 ± 0.089 1.58 ± 0.076∗∗
Patients with
SA+HT after
treatment
1.45 ± 0.047∗∗ 3.02 ± 0.079∗∗ 3.26 ± 0.026 1.93 ± 0.078 1.95 ± 0.078∗∗ 2.64 ± 0.079 2.41 ± 0.043∗∗
∗Reliability in relation to donors’ indicators.
∗∗Reliability in relation to pretreatment indicators at 𝑝 < 0.05.
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Figure 3: Change in the content of lipid peroxidation products in erythrocytic membranes of patients with SA and SA on the background of
hypertension (HT) in the course of treatment. ∗𝑝 < 0.05.
this group facilitated the recovery of fatty acid composition
in all studied fractions of phospholipids and the decrease in
the content of DC and MDA (Table 1, Figure 3). It should
be noted that in the group of patients with stable angina
on the background of hypertension the treatment had no
significant effect on the stabilisation of lipid composition of
biomembranes of formed blood elements.
The change in PL, FA of phospholipids, the accumulation
of FFA, DAG, and lysophospholipids observed in CVDs
indicate that the lipid phase is the very medium that defines
the structure and function of not only cell membranes, but
also the cell in general [44]. The leading role here belongs
to the lipolytic enzymes and oxidative processes in the lipid
phase.
Withmodification of lipid composition and the change in
the degree of unsaturation of fatty acid membranes the pack-
ing density of the lipid bilayer increases and microviscosity
of their membranes improves. And therefore, it is possible to
change the structure of erythrocyte.
The changes in morphology of the erythrocyte and, as
a consequence, the distribution of hemoglobin in it signifi-
cantly affect the efficiency of O2 transport within the body
and is a sign of many pathologies, including cardiovascular
disease [6].
Employing laser interference microscopy we examined
themorphology of erythrocytes in patients with stable angina
and patients with stable angina on the background of primary
hypertension (Figures 4 and 5).
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Figure 4: 3D simulation (a) and a profile (b) of human erythrocyte in norm, LIM image.
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Figure 5: 3D simulation (a) and phase profile (b) of SA patient’s erythrocyte, LIM image.
It is found that erythrocyte of a healthy donor has a nor-
mal discoidal shape, which is characterised by a uniform dis-
tribution of refraction index and, respectively, hemoglobin.
LIM imaging shows that the average the phase image
area of erythrocyte equates to 110.92 ± 1.76 𝜇m2 and the
erythrocyte volume makes 89.43 ± 2.37 𝜇m3.
Patients with stable angina have significant amounts of
structurally altered erythrocytes (Figure 5). Phase images
show that some erythrocytes, instead of a smooth dough-
nut shape, bear a “rough” shape with many irregularities
(Figure 5). Most likely, the erythrocyte’s rough shape in stable
angina patients is caused by changes in cytoskeleton structure
and hemoglobin redistribution in cytoplasm and submem-
branous areas.
These changes can be caused by pathological processes in
erythrocytes developing in hypoxic conditions.The proof for
the above is that the viscosity of the erythrocyte plasmatic
membrane and property of hemoglobin changes in condi-
tions of cardiovascular diseases [5]. It is the redistribution of
lipids and, consequently, their charge on the surface which
could affect the morphology of the erythrocyte. Besides, this
image can also illustrate the cell’s transition from discocyte to
echinocyte.
It is found that the phase image area of erythrocyte
decreases by 21.3% in SA patients. At the same time the ery-
throcyte volume increases by 42.2%, respectively, in relation
to control value (Table 2, Figure 6).
The erythrocytes can change their normal discoidal form
and be transformed into echinocytes along with an increase
in the area of their outer monolayer. Further transformation
is possible into stomatocytes in conjunction with an increase
in the area of the innermonolayer and into spherocytes.These
changes can be partly caused by pathological processes in
erythrocytes, including the condition when hypoxia devel-
ops, accompanying various manifestations of ischemic heart
disease. It is now clear that structural discrepancies may be
attributed to changes in the lipid composition of erythrocytic
membranes (Figures 6, 7, and 8).
In addition to the findings above, in SA patients and
SA+HT patients’ blood, the quantity of irreversible erythro-
cyte shapes, spherocytes for instance, increased (Figures 7
and 8). These changes were significantly marked in cardiac
angina without arterial hypertension.
The reversible transformation of a discocyte into an
echinocyte begins with impaired biconcave erythrocyte
structure contour with subsequent appearing of rough knots
on the disk circumference and then on the whole cell surface
BioMed Research International 7
Table 2: Distribution of erythrocytes sizes in the course of SA patients’ treatment and healthy persons (means ± SD).
Patients groups
Indicators
Phase image area of erythrocyte,
𝑆, 𝜇m2 Erythrocyte volume, 𝑉, 𝜇m
3 Themean value of optical path
difference (OPD),Φmean, 𝑛𝑚
Donors 110.92 ± 0.54 89.43 ± 3.63 60.92 ± 2.36
SA patients before treatment 87.35 ± 3.01∗ 126.29 ± 3.15∗ 108.44 ± 2.28∗
SA+HT patients before treatment 92.32 ± 4.77 109.21 ± 3.61 88.72 ± 4.30
SA patients after treatment 99.44 ± 2.45 118.47 ± 2.68∗∗ 89.35 ± 1.92
SA+HT patients after treatment 101.30 ± 1.95 108.88 ± 2.04 80.61 ± 1.51
∗Reliability in relation to donors’ indicators.
∗∗Reliability in relation to pretreatment indicators at 𝑝 < 0.05.
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Figure 6: 3D simulation (a) and phase profile (b) of SA patient’s erythrocyte, LIM image. Stomatocyte.
after which the erythrocyte generally takes a spherical shape.
Spherocyte formation represents the example of irreversible
erythrocyte deformation (Figure 8).
Changes in the phase profile in different types of ischemic
heart disease demonstrate redistribution and condensation of
intracellular contents, firstly hemoglobin.
Standard treatment administered for these diseases does
not bring any noticeable positive effect on normalisation of
morphometric erythrocyte characteristics.
As changes of morphometric indicators will undoubtedly
cause hemoglobin redistribution, it cannot fail to be reflected
on its oxygen transforming functions determined in turn by
conformation of hemoglobin hemoporphyrin.
Raman spectroscopy on the basis of hemoglobin hemo-
porphyrin spectra allows us to determine the oxidation
degree of the included ferrum atom, its spin condition, and
existence of ligands, reflecting the changes in globin structure
leading to deformation of hemoporphyrin and influencing
HB oxygen-binding properties.
The research into donors’ erythrocytes and ischemic
heart disease patients by means of RS showed changes in
conformation of hemoglobin hematoporphyrin in conditions
of hypoxia (Table 3).
Among other things found is the decrease in relative
quantity of oxyhemoglobin (o-Hb) and relative ability of
hemoglobin to isolate ligands for ischemic heart disease
patients in comparison with healthy donors’ indicators (by
28.9% and 46.5% for CA patients; by 40.7% and 37.9% for
SA+HT patients, resp.).
Among other things found is the decrease in relative
quantity of oxyhemoglobin (o-Hb) and relative ability of
hemoglobin to isolate ligands for ischemic heart disease
patients in comparison with healthy donors’ indicators (by
28.9% and 46.5% for SA patients; by 40.7% and 37.9% for
SA+HT patients, resp.).
Also we found the increase in relative ability of
hemoglobin to bind ligands (including oxygen) and affinities
of hemoglobin to ligands (first of all to oxygen) among SA
patients (by 33.8% and 45.3% in comparison with donors’
indicators) and SA with primary arterial hypertension
patients (by 56.9% and 38.2% in comparison with donors’
indicators).
Increased affinity of hemoglobin to oxygen and ability of
hemoglobin to bind oxygen further intensifies the hypoxic
processes already present when ischemic heart disease devel-
ops. Deterioration in ability of hemoglobin to release ligands
including oxygen leads to the same thing.
It is possible to assume that the increased affinity of
hemoglobin to oxygen and the arising hypoxia can be
an important decisive pathogenetic sign of ischemic heart
disease and arterial hypertension, as well as the cause
of its exacerbation when hypertensive crises follow. The
increased affinity of hemoglobin to oxygen reduces arteri-
ovenous differences with reference to oxygen and, therefore,
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Figure 7: 3D simulation (a) and phase profile (b) of SA patient’s erythrocyte, LIM image. Spherocyte formation.
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Figure 8: 3D simulation (a) and phase profile (b) of SA+HP patients’ erythrocyte, LIM image.
Table 3: Changes of oxygen binding ability of hemoglobin in the course of treatment of IHD patients and healthy persons (means ± SD).
Patients groups
Variants
Relative quantity of
o-Hb in blood, rel. Un.
𝐼1375/(𝐼1355 + 𝐼1375)
Relative ability of Hb to bind
ligands (including O2), rel. Un.
𝐼1355/𝐼1550
Relative ability of Hb to
isolate ligands, rel. Un.
𝐼1375/𝐼1580
Affinity of Hb to
ligands, first of all to
O2, rel. Un.
(𝐼1355/𝐼1550)/(𝐼1375/𝐼1580)
Donors 0.76 ± 0.02 0.65 ± 0.03 0.58 ± 0.02 1.28 ± 0.02
Patients before treatment
SA patients
before treatment 0.54 ± 0.03
∗ 0.87 ± 0.03∗ 0.31 ± 0.02∗ 1.86 ± 0.04∗
SA+HT patients
before treatment 0.45 ± 0.03
∗ 1.02 ± 0.03∗ 0.36 ± 0.02∗ 1.77 ± 0.04∗
Patients after treatment
SA patients after
treatment 0.63 ± 0.03
∗∗ 0.73 ± 0.03 0.45 ± 0.03∗∗ 1.26 ± 0.02∗∗
SA+HT patients
after treatment 0.49 ± 0.08
∗ 0.75 ± 0.07∗∗ 0.39+0.04 1.47 ± 0.04∗
∗Reliability in relation to donors’ indicators.
∗∗Reliability in relation to pretreatment indicators at 𝑝 < 0.05.
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aggravates not only cerebral hypoxia, but also other organs
and systems. Arising “vicious circles,” in their turn, can fur-
therworsen oxygen-transport function of blood [8]. Based on
treatment results the erythrocytes of patients with ischemic
heart disease (IHD) show better oxygen-binding capacity of
hemoglobin, but in healthy people this capacity was in most
cases much higher.
Therefore, to raise the efficiency of pathogenetic com-
prehensive treatment of patients with stable stenocardia and
arterial hypertension, it is necessary to include medication
relieving disturbances in the oxygen-transport function of
blood.
4. Discussion
The results of our own research and review of literature
on the topic prove that the change in physicochemical
properties of the lipid bilayer of erythrocytic membranes
largely determines the development of ischemic heart disease
(IHD).
It is possible to identify a number of factors that influence
the severity of the pathological processes in IHD: the accu-
mulation of phospholipids’ lysoforms (LPC and LPEA) and
free fatty acids in the development of IHD may contribute to
the “decondensation” of separate sections of the erythrocytic
membrane lipid bilayer [45].
Significant increase in the number of FFA also affects the
packing of bilayer integrity, influencing the increase in pas-
sive ion transport. All these processes impair gradients of ions
concentration and, as a consequence, disturb erythrocytes’
ionic balance [46].
Changes found in the content of PI and the simultaneous
accumulation ofDAG clearly point to the activation of the PI-
cycle and, therefore, to the intensification of processes leading
to the formation of secondary messengers which activate
protein kinase C.This subsequently triggers phosphorylation
and the activation of a large number of intracellular proteins.
This enhances Ca2+ permeability of erythrocytic mem-
branes, which in its turn may trigger activation of Ca2+-
dependent PLA2 [47].
The consequence of this is the strengthening of the
destructive processes in the membrane of red blood cells in
ischemic heart disease.
Changes of membrane lipid composition, in particular,
the increase of PS, DAG, and SM and reduction of PC, PEA,
and PI and the increase of lysoforms, trigger the disruption
of protein-lipid interactions in themembrane and change the
surface charge on the membrane.
In addition the change in the surface charge of the
erythrocytic membrane can be attributed to experimentally
found redistribution of charged fractions of phospholipids in
patients with stable angina in favour of those neutral ones,
located at the outer side of the plasma membrane (SM, LPC)
and negatively charged PS, which is part of the inner surface
of the membrane.
All these factors can also influence the transport of ions
and change the oxygen-binding properties of the erythrocyte
hemoglobin through the change in hematoporphyrin confor-
mation [6, 25, 48–50].
Intensification of LPO processes, found in IHD patients’
erythrocytes, firstly causes the decrease in the content of
unsaturated fatty acids of phospholipids which is more
marked in stable angina on the background of arterial hyper-
tension. This triggers the increase in membranes’ micro-
viscosity and enhances their clusterisation. As a result the
passive transport of ions including calcium ions increases due
to the formation of nonspecific pores [51].
In the end, the intensification of LPO processes along
with enzymatic degradation of PL contributes to membranes’
damage and changes their physicochemical properties. As a
result the disintegration of membrane structures culminates
in their destruction and eventual cell death may occur [52,
53].
Numerous processes in the lipid bilayer membrane lead
to changes in morphometric characteristics of erythro-
cytes among patients with IHD, namely, the appearance of
echinocytes, stomatocytes, and spherocytes with redistribu-
tion and condensation of hemoglobin within the cell. The
changes in morphology of the erythrocyte and, as a conse-
quence, distribution of hemoglobin within it, significantly
affect the O2 transport efficiency in the body and are signs
of many pathologies, including cardiovascular diseases [6].
The revealed hemoglobin hematoporphyrin conforma-
tion disturbance in IHD patients’ erythrocytes leads to the
impaired oxygen-binding capacity of hemoglobin exempli-
fied by the decrease in relative amount of oxyhemoglobin,
relative ability of hemoglobin to drop ligands, the enhanced
ability of hemoglobin to bind ligands, and the affinity of
hemoglobin to ligands. This contributes to further intensifi-
cation of the processes of hypoxia already present when IHD
develops.
Therefore, the above processes occurring in the lipid
bilayer of erythrocytic membranes affect the entire cytoar-
chitectonics of a cell, conformation of hemoglobin, and,
consequently, the core function of erythrocytes—transport
of oxygen. This mechanism is probably one of the most
important phases in the development of ischemic heart
disease.
The revealed changes in erythrocytes’ properties may also
worsen the tissue hypoxia and should be studied in further
experiments.
5. Conclusion
The research findings showed that erythrocytic membranes,
cytoarchitectonics of formed elements, lipids forming lipid
membranes bilayer, and also hemoglobin represent a uniform
highly dynamic system responding to the changes happening
in the human body.
Based on findings and scientific literature it is possi-
ble to state that the prescribed therapy did not lead to
normalisation of phospholipid and fatty acid structure of
erythrocytic membranes. It requires a further search for
natural compounds that can influence phospholipase activity
and normalise processes of lipid peroxidation and, finally,
the structure of hemoglobin. Traditional treatment does
not affect one of the major phases of tissue oxygen supply
or separate sites exposed to hypoxia. In order to advance
10 BioMed Research International
the management of cardiovascular diseases it is necessary to
take into account the possibility of administering medication
improving the functional characteristics of both hemoglobin
and erythrocytes.
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